Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). A recent whole genome association study highlighted a strong association with allopurinol-induced SJS/TEN within the HCP5 and PSORS1C1 genes in the Japanese population. Our aim was to verify the contribution of these two genes in the susceptibility to NVP-induced SJS/TEN in a population from Mozambique.
Borgiani, P., Di Fusco, D., Erba, F., Marazzi, M., Mancinelli, S., Novelli, G., et al. (2014). HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 70(3), 275-278 [10.1007/s00228-013-1622-5].
HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique
BORGIANI, PAOLA;ERBA, FULVIO;MANCINELLI, SANDRO;NOVELLI, GIUSEPPE;PALOMBI, LEONARDO;CICCACCI, CINZIA
2014-03-01
Abstract
Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). A recent whole genome association study highlighted a strong association with allopurinol-induced SJS/TEN within the HCP5 and PSORS1C1 genes in the Japanese population. Our aim was to verify the contribution of these two genes in the susceptibility to NVP-induced SJS/TEN in a population from Mozambique.| File | Dimensione | Formato | |
|---|---|---|---|
|
HCP5 genetic variant (RS3099844) contributes to Nevirapine.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
235.18 kB
Formato
Adobe PDF
|
235.18 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
